Sachie Marubayashi
About Sachie Marubayashi
Sachie Marubayashi is an Associate Scientist at Arcus Biosciences, with a background in Genetics and Forensic Science. She has held various research positions in prominent institutions, contributing to studies in cancer treatment and immunotherapy.
Work at Arcus Biosciences
Sachie Marubayashi has been employed at Arcus Biosciences as an Associate Scientist since 2019. In this role, she contributes to research and development efforts focused on innovative cancer therapies. Her work involves collaboration with multidisciplinary teams to advance the understanding of immunotherapy and its applications in oncology.
Education and Expertise
Sachie Marubayashi earned a Bachelor of Science (B.S.) degree from the University of California, Davis, where she studied Genetics and Comparative Literature from 2001 to 2006. She furthered her education by obtaining a Master's degree in Forensic Science from Drexel University College of Medicine, completing her studies from 2012 to 2014. Her academic background provides a strong foundation for her research in the life sciences.
Previous Work Experience
Prior to her current position, Sachie Marubayashi held several roles in prominent research institutions. She worked as a Senior Research Technician at Memorial Sloan-Kettering Cancer Center from 2007 to 2011. Following that, she served as a Senior Research Associate at Flexus Biosciences for five months in 2014 and at FLX Bio, Inc. from 2015 to 2017. She also worked as an Associate Scientist at FLX Bio, Inc. from 2018 to 2019. Additionally, she was a Laboratory Technician at Columbia University Medical Center from 2006 to 2007.
Research Contributions
Sachie Marubayashi has actively participated in significant research initiatives. In November 2023, she presented research at the Society for Immunotherapy of Cancer (SITC), focusing on the combined administration of etrumadenant with a reduced chemotherapy regimen. She also co-authored a study on the dual A2aR/A2bR antagonist etrumadenant, which was presented at the American Association for Cancer Research (AACR) in April 2022.